Search Within

Lara Dunn

Formats
  1. Meeting Abstract (81)
  2. Journal Article (50)
  3. Review (7)
  4. Book Section (1)
  5. Editorial (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (141)
  2. Head and Neck Service (141)
  3. Solid Tumor Oncology Division (141)
  4. Weinberg Fellows (141)
  5. Radiation Oncology, Department of (72)
  6. Surgery (65)

More Groups

People
  1. Eric Sherman (77)
  2. David Pfister (60)
  3. Nancy Lee (60)
  4. Sean McBride (57)
  5. Alan Ho (54)
  6. Nadeem Riaz (52)

More People

Years
  1. 2025 (3)
  2. 2024 (22)
  3. 2023 (10)
  4. 2022 (11)
  5. 2021 (23)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (41)
  2. International Journal of Radiation Oncology, Biology, Physics (24)
  3. Annals of Oncology (9)
  4. Journal for ImmunoTherapy of Cancer (8)
  5. Head & Neck (6)
  6. Oral Oncology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (43)
  2. Elsevier Inc. (30)
  3. Oxford University Press (10)
  4. Biomed Central Ltd (8)
  5. John Wiley & Sons, Inc. (6)
  6. Wiley Blackwell (6)

More Publishers

Results (141)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An open-label, phase II, multicenter, single-arm study of induction and concurrent vismodegib combined with curative-intent radiation therapy for locally advanced basal cell carcinoma
    Meeting Abstract

    Yom, S.; Arron, S.; Ho, A.; Algazi, A.; Dunn, L.; Tsai, C. J.; Humphries, A.; Hultman, C.; Grekin, R.; Knott, P. D.; more...
    American Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise
    Review

    Zakeri, K.; Dunn, L.; Lee, N.
    Journal of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy vs intensity-modulated radiation therapy
    Journal Article

    Li, X.; Kitpanit, S.; Lee, A.; Mah, D.; Sine, K.; Sherman, E. J.; Dunn, L. A.; Michel, L. S.; Fetten, J.; Zakeri, K.; more...
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Metastatic cutaneous squamous cell carcinoma involving the parotid gland: Experience outside of the sun belt
    Journal Article

    Flukes, S.; Long, S.; Lohia, S.; Barker, C. A.; Dunn, L. A.; Cracchiolo, J.; Ganly, I.; Patel, S.; Cohen, M. A.
    OTO Open (2021)

    Fulltext@MSK | Save
  • Any day, split halfway: Flexibility in scheduling high-dose cisplatin - A large retrospective review from a high-volume cancer center
    Journal Article

    Kang, J. J.; Tchekmedyian, V.; Mohammed, N.; Rybkin, A.; Kitpanit, S.; Fan, M.; Wang, H.; Lobaugh, S. M.; Zhang, Z.; Lee, A.; more...
    International Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Journal Article

    Lee, N. Y.; Ferris, R. L.; Psyrri, A.; Haddad, R. I.; Tahara, M.; Bourhis, J.; Harrington, K.; Chang, P. M. H.; Lin, J. C.; Razaq, M. A.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy
    Journal Article

    Zakeri, K.; Wang, H.; Kang, J. J.; Lee, A.; Romesser, P.; Mohamed, N.; Gelblum, D.; Sherman, E.; Dunn, L.; Boyle, J.; more...
    Head & Neck (2021)

    Fulltext@MSK | Save
  • Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
    Journal Article

    McBride, S.; Sherman, E.; Tsai, C. J.; Baxi, S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D.; Michel, L. S.; Young, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
    Journal Article

    Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS)
    Meeting Abstract

    Lewis, K.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A. L.; Migden, M.; Li, S.; Mohan, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save